A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer
Background: Necroptosis has been demonstrated to play a crucial role in the prognosis prediction and assessment of treatment outcome in cancers, including cervical cancer. The purpose of this study was to explore the potential prognostic value of necroptosis-related lncRNAs and their relationship wi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.938250/full |
| _version_ | 1811185906191695872 |
|---|---|
| author | Xinyi Du Xiaowen Pu Xintao Wang Yuchen Zhang Ting Jiang Yanjun Ge Haiyan Zhu |
| author_facet | Xinyi Du Xiaowen Pu Xintao Wang Yuchen Zhang Ting Jiang Yanjun Ge Haiyan Zhu |
| author_sort | Xinyi Du |
| collection | DOAJ |
| description | Background: Necroptosis has been demonstrated to play a crucial role in the prognosis prediction and assessment of treatment outcome in cancers, including cervical cancer. The purpose of this study was to explore the potential prognostic value of necroptosis-related lncRNAs and their relationship with immune microenvironment and response to treatment in cervical cancer.Methods: Data from The Cancer Genome Atlas (TCGA) were collected to obtain synthetic data matrices. Necroptosis-related lncRNAs were identified by Pearson Correlation analysis. Univariate Cox and multivariate Cox regression analysis and Lasso regression were used to construct a necroptosis-related LncRNAs signature. Kaplan-Meier analysis, univariate and multivariate Cox regression analyses, receiver operating characteristic (ROC) curve, nomogram, and calibration curves analysis were performed to validate this signature. Gene set enrichment analyses (GSEA), immunoassays, and the half-maximal inhibitory concentration (IC50) were also analyzed.Results: Initially, 119 necroptosis-related lncRNAs were identified based on necroptosis-related genes and differentially expressed lncRNAs between normal and cervical cancer samples. Then, a prognostic risk signature consisting of five necroptosis-related lncRNAs (DDN-AS1, DLEU1, RGS5, RUSC1-AS1, TMPO-AS1) was established by Cox regression analysis, and LASSO regression techniques. Based on this signature, patients with cervical cancer were classified into a low- or high-risk group. Cox regression confirmed this signature as an independent prognostic predictor with an AUC value of 0.789 for predicting 1-year OS. A nomogram including signature, age, and TNM stage grade was then established, and showed an AUC of 0.82 for predicting 1-year OS. Moreover, GSEA analysis showed that immune-related pathways were enriched in the low-risk group; immunoassays showed that most immune cells, ESTIMAT scores and immune scores were negatively correlated with risk score and that the expression of immune checkpoint-proteins (CD27, CD48, CD200, and TNFRSF14) were higher in the low-risk group. In addition, patients in the low-risk group were more sensitive to Rucaparib, Navitoclax and Crizotinib than those in the high-risk group.Conclusion: We established a novel necroptosis-related lncRNA based signature to predict prognosis, tumor microenvironment and response to treatment in cervical cancer. Our study provides clues to tailor prognosis prediction and individualized immunization/targeted therapy strategies. |
| first_indexed | 2024-04-11T13:37:18Z |
| format | Article |
| id | doaj.art-24ba47d733244fad956c958123568806 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-11T13:37:18Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-24ba47d733244fad956c9581235688062022-12-22T04:21:24ZengFrontiers Media S.A.Frontiers in Genetics1664-80212022-12-011310.3389/fgene.2022.938250938250A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancerXinyi DuXiaowen PuXintao WangYuchen ZhangTing JiangYanjun GeHaiyan ZhuBackground: Necroptosis has been demonstrated to play a crucial role in the prognosis prediction and assessment of treatment outcome in cancers, including cervical cancer. The purpose of this study was to explore the potential prognostic value of necroptosis-related lncRNAs and their relationship with immune microenvironment and response to treatment in cervical cancer.Methods: Data from The Cancer Genome Atlas (TCGA) were collected to obtain synthetic data matrices. Necroptosis-related lncRNAs were identified by Pearson Correlation analysis. Univariate Cox and multivariate Cox regression analysis and Lasso regression were used to construct a necroptosis-related LncRNAs signature. Kaplan-Meier analysis, univariate and multivariate Cox regression analyses, receiver operating characteristic (ROC) curve, nomogram, and calibration curves analysis were performed to validate this signature. Gene set enrichment analyses (GSEA), immunoassays, and the half-maximal inhibitory concentration (IC50) were also analyzed.Results: Initially, 119 necroptosis-related lncRNAs were identified based on necroptosis-related genes and differentially expressed lncRNAs between normal and cervical cancer samples. Then, a prognostic risk signature consisting of five necroptosis-related lncRNAs (DDN-AS1, DLEU1, RGS5, RUSC1-AS1, TMPO-AS1) was established by Cox regression analysis, and LASSO regression techniques. Based on this signature, patients with cervical cancer were classified into a low- or high-risk group. Cox regression confirmed this signature as an independent prognostic predictor with an AUC value of 0.789 for predicting 1-year OS. A nomogram including signature, age, and TNM stage grade was then established, and showed an AUC of 0.82 for predicting 1-year OS. Moreover, GSEA analysis showed that immune-related pathways were enriched in the low-risk group; immunoassays showed that most immune cells, ESTIMAT scores and immune scores were negatively correlated with risk score and that the expression of immune checkpoint-proteins (CD27, CD48, CD200, and TNFRSF14) were higher in the low-risk group. In addition, patients in the low-risk group were more sensitive to Rucaparib, Navitoclax and Crizotinib than those in the high-risk group.Conclusion: We established a novel necroptosis-related lncRNA based signature to predict prognosis, tumor microenvironment and response to treatment in cervical cancer. Our study provides clues to tailor prognosis prediction and individualized immunization/targeted therapy strategies.https://www.frontiersin.org/articles/10.3389/fgene.2022.938250/fullnecroptosis-related lncRNAcervical cancerimmuneprognostic modelrisk score |
| spellingShingle | Xinyi Du Xiaowen Pu Xintao Wang Yuchen Zhang Ting Jiang Yanjun Ge Haiyan Zhu A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer Frontiers in Genetics necroptosis-related lncRNA cervical cancer immune prognostic model risk score |
| title | A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer |
| title_full | A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer |
| title_fullStr | A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer |
| title_full_unstemmed | A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer |
| title_short | A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer |
| title_sort | novel necroptosis related lncrna based signature predicts prognosis and response to treatment in cervical cancer |
| topic | necroptosis-related lncRNA cervical cancer immune prognostic model risk score |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2022.938250/full |
| work_keys_str_mv | AT xinyidu anovelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT xiaowenpu anovelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT xintaowang anovelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT yuchenzhang anovelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT tingjiang anovelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT yanjunge anovelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT haiyanzhu anovelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT xinyidu novelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT xiaowenpu novelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT xintaowang novelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT yuchenzhang novelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT tingjiang novelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT yanjunge novelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer AT haiyanzhu novelnecroptosisrelatedlncrnabasedsignaturepredictsprognosisandresponsetotreatmentincervicalcancer |